Merck's Cozaar Loses Patent Protection In Europe And Generics Quickly Arrive
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic competition starts in Europe for Merck blockbuster Cozaar heart drug.
You may also be interested in...
Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Merck/Schering: The Next Wave Of Consolidation
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion